ClinicalTrials.Veeva

Menu

Inflammatory Response as a Prognostic Factor of Recurrence of Atrial Fibrillation After Ablation (ACtIVE-AF)

M

Medical University of Warsaw

Status

Unknown

Conditions

Atrial Fibrillation

Study type

Observational

Funder types

Other

Identifiers

NCT02844959
KB/143/2016

Details and patient eligibility

About

The aim of this study is to evaluate inflammatory response as a prognostic factor of atrial fibrillation recurrency after ablation. Inflammatory response will be assessed by double measurement of C-reactive protein, fibroblast growth factor 2 (FGF2), matrix metallopeptidase 8 (MMP8) and body temperature. Dynamics of change of troponin I will be measured additionally.

After ablation each patient will be monitored with ECG telemonitoring system for 7 days.

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • signed consent;
  • criteria for ablation of atrial fibrillation.

Exclusion criteria

  • previous pulmonary veins isolation;
  • ablation other than pulmonary veins isolation during the procedure;
  • atrial fibrillation at the beginning of ablation procedure;
  • usage of 'single shot' devices.

Trial contacts and locations

1

Loading...

Central trial contact

Krzysztof Ozierański, MD; Michał Peller, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems